News Focus
News Focus
icon url

DewDiligence

08/29/11 4:27 PM

#125847 RE: NP1986 #125845

No, but good guess. RE-LY (http://www.clinicaltrials.gov/ct2/show/NCT00262600 ) was the only phase-3 trial for Pradaxa in AF. It was blinded with respect to the two doses of Pradaxa, but open-label with respect to the warfarin arm.